Insulet (PODD) recently disclosed a voluntary device correction for certain Omnipod 5 lots after 18 serious adverse events, including hospitalizations and diabetic ketoacidosis, while affirming its existing outlook and excluding remediation costs from non GAAP results.

The voluntary device correction and recent executive appointments come at a time of softer share performance, with a 30 day share price return of 15.65% and a 1 year total shareholder return of 23.07%. This suggests that momentum has been fading even after strong recent earnings updates.

If this kind of healthcare technology story interests you, it could be a good moment to widen your search using our screener for 33 healthcare AI stocks

With Insulet shares down over the past year and trading at a discount to some analyst targets despite double digit revenue and net income growth, investors may be asking whether the recent weakness is opening a window of opportunity or whether the market is already pricing in potential future gains.

Most Popular Narrative: 41.1% Undervalued

With Insulet shares at $207.04 versus a narrative fair value of $351.43, the current price sits well below what this widely followed model suggests, putting the focus squarely on how long term growth in automated insulin delivery could support that gap.

Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets, driven by strong clinical evidence, ease of use, and superior integration with the latest glucose sensors, is positioning Insulet to capture a disproportionately large share of the expanding global diabetes device market, supporting outsized top-line revenue growth for several years.

Read the complete narrative. Read the complete narrative.

Curious how a single product platform, expanding indications, and international rollout translate into that higher fair value. The model leans heavily on sustained revenue expansion, rising margins, and a premium future earnings multiple that outstrips many medical equipment peers.

Result: Fair Value of $351.43 (UNDERVALUED)

However, that upside view still depends on Omnipod staying ahead of rising patch pump competition and on future product issues not weighing more heavily on adoption or margins.

Another View: Rich P/E Tempering the Undervaluation Story

While the narrative fair value of $351.43 suggests Insulet could be undervalued, the current P/E of 59x tells a different story. That is well above the US Medical Equipment industry at 27.5x, the peer average at 37.8x, and even the 30.8x fair ratio that the market could move toward over time. For investors, that gap means paying a high price for growth expectations, so the key question is whether the earnings outlook truly justifies this premium.

Next Steps

With sentiment clearly split between a rich P/E and a bullish fair value, this is a moment to move quickly and test the story against your own judgment using the detailed breakdown of 3 key rewards and 2 important warning signs.

Ready for more investment ideas?

If Insulet has caught your attention, do not stop here, broaden your watchlist with other focused stock ideas that fit different goals and risk levels.

• Target potential upside in smaller companies by scanning carefully filtered 31 elite penny stocks with strong financials that already show stronger balance sheets and financial quality than many peers.
• Zero in on value opportunities by reviewing 63 high quality undervalued stocks where solid fundamentals and pricing may line up more favorably than widely followed names.
• Prioritize resilience by checking 65 resilient stocks with low risk scores built around companies with lower risk scores that could suit a steadier core in your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.